August 19, 2026 08:35 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Supreme Court rejects ‘less painful’ death penalty plea, but leaves door open for future change | ‘Vulgarity and disgust’: DMK attacks Vijay over Trisha salute at I-Day event | ‘Take Gyanesh Kumar to the US’: Congress mocks Trump over praise for India’s voter ID system | Big relief for Imran Khan: Pakistan Supreme Court orders hospital transfer amid health fears | Trump praises India’s voter ID system, pushes SAVE America Act | Trump's shock threat to bomb Oman: US President warns ally over Iran deal and Hormuz crisis | Rishabh Pant scripts history! Indian wicketkeeper-batter joins elite 100-sixes club in Test cricket | BJP reshuffles top organisation seven months after Nitin Nabin's elevation | West Bengal STF arrests suspected aide of ISI 'agent' Rana Rauf in Kolkata | ‘Very hopeful’: Indian envoy Dinesh Trivedi breaks silence on PM Tarique Rahman’s proposed India visit
US Tariffs
A view inside a pharmacy’s automated medication storage facility. Photo: Jan Woitas/dpa-Zentralbild/dpa

US tariffs seen as threat to European pharma production, industry says

| @indiablooms | Apr 04, 2026, at 12:09 am

Pharmaceutical manufacturers in Germany and Switzerland on Friday warned that the latest US tariffs on pharmaceutical products could threaten production at their European facilities, industry representatives said.

"In the medium term, there is a risk that parts of production and research will move to the US," where regulatory and financial incentives are attractive, said the Association of Research-Based Pharmaceutical Companies (VFA) in Berlin.

The Swiss association Interpharma warned of negative consequences for patients.

The US administration seeks to encourage pharmaceutical companies to set up operations in the US by imposing a 100% surcharge.

However, Germany and all other EU member states, as well as Switzerland, Japan and South Korea, are exempt from this due to separate agreements. Tariff rates of up to 15% apply to them.

Nevertheless, the pharmaceutical associations view the new measures as a massive intervention in the medicines market.

The tariffs "jeopardise global production and supply chains for medicines, hinder research and development, and ultimately harm patients worldwide", Interpharma warned.

Individual manufacturers can avoid tariffs by increasing investment and production in the United States and by lowering their prices there.

Among others, the Swiss industry giants Novartis and Roche concluded agreements with the US government in December with this in mind.

Amid pressure from the US, investments in Germany are now also under scrutiny, VFA President Han Steutel said, adding that this makes it all the more important to develop a significant market in Europe as well.

He called for lower establishment costs, faster procedures and support for innovation.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.